PAP
TRVI icon

Persistent Asset Partners’s Trevi Therapeutics TRVI Stock Holding History

Persistent Asset Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$477K Sell
25,601
-2,312
-8% -$33.6K 0.14% 118
2026
Q1 		$333K Sell
27,913
-17,917
-39% -$201K 0.12% 142
2025
Q4 		$574K Buy
45,830
+26,142
+133% +$302K 0.26% 108
2025
Q3 		$180K Sell
19,688
-23,100
-54% -$173K 0.12% 135
2025
Q2 		$234K Buy
42,788
+1,384
+3% +$8.61K 0.17% 107
2025
Q1 		$260K Buy
+41,404
New +$198K 0.22% 87

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Persistent Asset Partners's TRVI Position: Q2 2026 in Review

Persistent Asset Partners reduced its Trevi Therapeutics (TRVI) stake by 8.3% in Q2 2026, selling an estimated $33.6K and leaving 25,601 shares worth $477K. The position accounts for 0.14% of the portfolio, ranked #118.

Persistent Asset Partners first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. The position peaked at $574K in Q4 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Persistent Asset Partners held 25,601 shares of Trevi Therapeutics worth $477K as of Q2 2026.
  • Persistent Asset Partners sold 2,312 Trevi Therapeutics shares in Q2 2026, an estimated $33.6K.
  • Trevi Therapeutics made up 0.14% of Persistent Asset Partners's portfolio in Q2 2026, its #118 holding.
  • Persistent Asset Partners first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Persistent Asset Partners's Trevi Therapeutics position peaked at $574K in Q4 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.